1-乙烯基环己烯 、 2-prenyloxy-1,4-benzoquinone 以
甲醇 为溶剂,
反应 3.0h,
以3-Prenyloxy-5,6,7,8-tetrahydro-1,4-phenanthrenequinone (1.61 g, 5.44 mM) was obtained in the same manner as in Example 1的产率得到3-prenyloxy-5,6,7,8-tetrahydro-1,4-phenanthrenequinone
参考文献:
名称:
NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME
Phenanthrenequinone-based compound and pharmaceutical composition containing the same for the treatment or prevention of disease involving metabolic syndrome
申请人:Yoo Sang-Ku
公开号:US08404869B2
公开(公告)日:2013-03-26
Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof.
[EN] NOVEL PHENANTHRENEQUINONE-BASED COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME FOR THE TREATMENT OR PREVENTION OF DISEASE INVOLVING METABOLIC SYNDROME<br/>[FR] NOUVEAU COMPOSÉ À BASE DE PHÉNANTHRÈNEQUINONE ET COMPOSITION PHARMACEUTIQUE CONTENANT CE DERNIER UTILISÉ POUR LE TRAITEMENT OU LA PRÉVENTION DU SYNDROME MÉTABOLIQUE IMPLIQUANT DES MALADIES
申请人:MAZENCE INC
公开号:WO2008133441A1
公开(公告)日:2008-11-06
[EN] Provided is a pharmaceutical composition for the treatment and/or prevention of disease involving metabolic syndromes, comprising (a) a therapeutically effective amount of a particular compound represented by Formula 1 as defined in the specification, or isomer, prodrug, or solvate or thereof, and (b) a pharmaceutically acceptable carrier, a diluent or an excipient, or any combination thereof. [FR] La présente invention concerne une composition pharmaceutique utile pour le traitement et/ou la prévention des syndromes métaboliques impliquant des maladies. La composition pharmaceutique contient (a) une quantité thérapeutiquement efficace d'un composé particulier représenté par la formule I telle que définie dans la description, ou bien un isomère, un promédicament ou un solvate de ce dernier, et (b) un support pharmaceutiquement acceptable, un diluant ou un excipient, ou une combinaison de ces derniers.